← All trials
NCT04839341
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 24, 2021
- Primary completion
- Dec 31, 2022
- Completion date
- Feb 28, 2023
- First posted
- Apr 9, 2021
- Last posted
- Sep 16, 2021
- Enrollment
- 12
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Apollomics, Inc.Lead sponsor
- Sheffield Hallam UniversityOverall official - principal investigator
- Zhejiang CrownMab Biotech Co. LtdCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.